×
Home Current Archive Editorial board
News Contact
Research paper

Comparative pharmacoepidemiological analysis on analgesics consumption in the Republic of Serbia and Nordic countries in the period 2015-2018

By
Dane Krtinić Orcid logo ,
Dane Krtinić

University of Nis , Niš , Serbia

Boris Milijašević Orcid logo ,
Boris Milijašević

University of Novi Sad , Novi Sad , Serbia

Aleksandra Dragić ,
Aleksandra Dragić

University of Novi Sad , Novi Sad , Serbia

Dragana Milijašević Orcid logo ,
Dragana Milijašević

University of Novi Sad , Novi Sad , Serbia

Aleksandra Lučić-Prokin Orcid logo ,
Aleksandra Lučić-Prokin

University of Novi Sad , Novi Sad , Serbia

Gordana Nedin-Ranković Orcid logo ,
Gordana Nedin-Ranković

University of Nis , Niš , Serbia

Irena Conić Orcid logo ,
Irena Conić

Klinički centar Niš , Niš , Serbia

Mirjana Todorović-Mitić ,
Mirjana Todorović-Mitić

Klinički centar Niš , Niš , Serbia

Hristina Jovanović Orcid logo ,
Hristina Jovanović

University of Nis , Niš , Serbia

Hristina Trajković Orcid logo ,
Hristina Trajković

University of Nis , Niš , Serbia

Vuk Pejčić
Vuk Pejčić

Klinički centar Niš , Niš , Serbia

Abstract

Introduction/Aim. Analgesics are drugs used in the pain pharmacotherapy and are one of the most prescribed drugs in all countries. Modern pain pharmacotherapy involves the use of analgesic steps. The objective of this paper was to analyze the consumption of drugs used in the pain pharmacotherapy in the Republic of Serbia (RS), in the period from 2015 to 2018, and to compare the obtained results with the consumption of the mentioned drugs in the Kingdom of Norway (KN) and the Republic of Finland (RF) in the same time period interval. Material and methods. Data on drug consumption were taken from the website of the Agency for Medicines and Medical Devices of Serbia, the official website of the Norwegian Institute of Public Health and from the official website of the Finnish Medicines Agency. The consumption of medicines is monitored using the defined daily dose (DDD) methodology. Results. Paracetamol consumption was 13 to even 20 times lower in the RS compared to the KN and 10 to 15 times lower compared to the RF. The average consumption of diclofenac during the four observed years was about 30 DDD/1,000 inhabitants/day in the RS, about 7 in the KN and about 4 DDD/1,000 inhabitants/day in the RF. Conclusion. In the pain pharmacotherapy in the RS, the consumption of non-steroidal anti-inflammatory drugs is dominated by diclofenac, while in the KN and the RF ibuprofen and paracetamol from non-opioids.

References

1.
Radonjić V. Promet i potrošnja lekova za humanu upotrebu u Republici Srbiji 2018. 2019.
2.
Gatti D, Adami S. Coxibs: a significant therapeutic opportunity. Acta Biomed. 2010;81(3):217–24.
3.
Ha MW, Paek SM. Recent Advances in the Synthesis of Ibuprofen and Naproxen. Molecules. 26(16):4792.
4.
Singla AK, Chawla M, Singh A. Review Nimesulide: Some Pharmaceutical and Pharmacological Aspects—An Update. Journal of Pharmacy and Pharmacology. 2000;52(5):467–86.
5.
Irvine J, Afrose A, Islam N. Formulation and delivery strategies of ibuprofen: challenges and opportunities. Drug Development and Industrial Pharmacy. 2018;44(2):173–83.
6.
Chinese Rheumatism Data Center; Chinese Systemic Lupus Erythematosus Treatment and Research Group. Recommendation for the prevention and treatment of non-steroidal antiinflammatory drug-induced gastrointestinal ulcers and its complications. Zhonghua Nei Ke Za Zhi. 2017;56(1):81–5.
7.
Gan TJ. Diclofenac: an update on its mechanism of action and safety profile. Current Medical Research and Opinion. 2010;26(7):1715–31.
8.
Kaye AD. Tramadol, Pharmacology, Side Effects, and Serotonin Syndrome: A Review. Pain Physician. 2015;18;4(4;18):395–400.
9.
Trescot AM. Opioid Pharmacology. Pain Physician. 2008;2s;11(3;2s):S133–53.
10.
Tomić Z, Sabo A, Horvat O, Milijašević B. Osnovi farmakoekonomije i farmakoepidemiologije. 2020.
11.
WHO Collaborating Centre for Drug Statistics Methodology, ATC classification index with DDDs, 2022. 2021;
12.
Finnish Medicines Agency Fimea. In: Finnish Statistics on Medicines 2015-2018. 2023.
13.
Norwegian Institute for Public Health. Drug Consumption in Norway 2015-2018. 2023.
14.
Aydede M. Does the IASP definition of pain need updating? PAIN Reports. 4(5):e777.
15.
Radonjić V. Promet i potrošnja lekova za humanu upotrebu u Republici Srbiji 2017. 2018.
16.
Radonjić V. Promet i potrošnja lekova za humanu upotrebu u Republici Srbiji 2016. 2017.
17.
Radonjić V. Promet i potrošnja lekova za humanu upotrebu u Republici Srbiji 2015. 2016.
18.
Portenoy RK. A Practical Approach to Using Adjuvant Analgesics in Older Adults. Journal of the American Geriatrics Society. 2020;68(4):691–8.
19.
OLDHAM JM. Opioids. Journal of Psychiatric Practice. 2020;26(1):1–2.
20.
Garcia Rodriguez LA, Cea-Soriano L, Tacconelli S, Patrignani P. Coxibs: Pharmacology, Toxicity and Efficacy in Cancer Clinical Trials. Recent Results in Cancer Research. 2013. p. 67–93.
21.
Bacchi S, Palumbo P, Sponta A, Coppolino MF. Clinical Pharmacology of Non-Steroidal Anti-Inflammatory Drugs: A Review. Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry. 2012;11(1):52–64.
22.
Jóźwiak-Bebenista M, Nowak JZ. Paracetamol: mechanism of action, applications and safety concern. Acta Pol Pharm. 2014;71(1):11–23.
23.
Stevanović P, Nešić D, Lađević N. Medicina bola. 2020;
24.
Danilov A, Danilov A, Barulin A, Kurushina O, Latysheva N. Interdisciplinary approach to chronic pain management. Postgraduate Medicine. 2020;132(sup3):5–9.
25.
Republička stručna komisija za izradu i implementaciju vodiča u kliničkoj praksi; Nacionalni vodič dobre kliničke prakse za dijagnostikovanje i lečenje hroničnog bola maligne etiologije. In: Ministarstvo zdravlja Republike Srbije. 2013.

Citation

Article metrics

Google scholar: See link

The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.